Blend Vial strength 10 mg Blend
CJC-1295 NO DAC + Ipamorelin10 mg Blend
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
CJC-1295 NO DAC + Ipamorelin, explained simply
A blend of a shorter-acting GHRH analogue and ipamorelin, a growth hormone secretagogue.
Research area
GH axis and pulsatile signalling
How it works
The components act on the GHRH and ghrelin receptors respectively, two complementary pathways for GH release.
Why it matters
Researchers examine the hormonal response produced by combining these signals.
What has been observed
GH and IGF-1 data chiefly concern the components and the biological rationale for pairing them.
Effects and points to consider
Individual peptide findings do not quantify a clinical benefit of the prepared blend. Temporary effects such as flushing or headache may occur.
01 / Vial strength 10 mg Blend
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Total vial mass | 10 mg |
|---|---|
| Component masses | CJC-1295 NO DAC: 5 mg; Ipamorelin: 5 mg |
| Final volume | 3 mL |
| Concentration | 3.33 mg/mL |
| Frequency | once daily |
| Cycle | 12 in table |
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Daily Dose (mcg each) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.